Parkinson's Disease Dementia (PDD) Clinical Trial
Official title:
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
The purpose of this study placebo-controlled, randomized, double-blind study is to assess the safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD) already treated with a stable dose of a cholinesterase inhibitor.
This study includes a Screening Period of up to 6 weeks, a 16 week Treatment Period, and a 2
week Safety Follow Up Period.
Final eligibility will be determined at the Baseline Visit. Eligible patients will be
randomized to receive placebo or SYN120 100 mg once a day (QD).
;